BE2012C050I2 - - Google Patents

Download PDF

Info

Publication number
BE2012C050I2
BE2012C050I2 BE2012C050C BE2012C050C BE2012C050I2 BE 2012C050 I2 BE2012C050 I2 BE 2012C050I2 BE 2012C050 C BE2012C050 C BE 2012C050C BE 2012C050 C BE2012C050 C BE 2012C050C BE 2012C050 I2 BE2012C050 I2 BE 2012C050I2
Authority
BE
Belgium
Application number
BE2012C050C
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23001755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2012C050(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of BE2012C050I2 publication Critical patent/BE2012C050I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
BE2012C050C 2001-01-23 2012-11-29 BE2012C050I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26343501P 2001-01-23 2001-01-23
PCT/US2002/001963 WO2002058737A2 (fr) 2001-01-23 2002-01-22 Vaccin meningococcique polyvalent prrepare avec un conjugue de polysaccharide et de proteine

Publications (1)

Publication Number Publication Date
BE2012C050I2 true BE2012C050I2 (fr) 2021-03-23

Family

ID=23001755

Family Applications (3)

Application Number Title Priority Date Filing Date
BE2012C050C BE2012C050I2 (fr) 2001-01-23 2012-11-29
BE2015C077C BE2015C077I2 (fr) 2001-01-23 2015-12-15
BE2022C502C BE2022C502I2 (fr) 2001-01-23 2022-01-06

Family Applications After (2)

Application Number Title Priority Date Filing Date
BE2015C077C BE2015C077I2 (fr) 2001-01-23 2015-12-15
BE2022C502C BE2022C502I2 (fr) 2001-01-23 2022-01-06

Country Status (38)

Country Link
US (9) US8722062B2 (fr)
EP (3) EP2332581B1 (fr)
JP (6) JP2005504718A (fr)
KR (2) KR100947751B1 (fr)
CN (1) CN100556459C (fr)
AP (1) AP1897A (fr)
AU (2) AU2007216743A1 (fr)
BE (3) BE2012C050I2 (fr)
BR (1) BRPI0206672B8 (fr)
CA (1) CA2435681C (fr)
CR (1) CR7035A (fr)
CY (2) CY1113072T1 (fr)
DK (2) DK1355673T3 (fr)
EA (1) EA006947B1 (fr)
EC (1) ECSP034701A (fr)
ES (3) ES2388848T3 (fr)
FR (3) FR12C0072I2 (fr)
GE (1) GEP20053691B (fr)
HR (1) HRP20030598B1 (fr)
HU (2) HU230490B1 (fr)
IL (3) IL157060A0 (fr)
IS (1) IS6881A (fr)
LT (1) LT5177B (fr)
LU (1) LU92108I2 (fr)
LV (1) LV13128B (fr)
MX (2) MXPA03006561A (fr)
NO (1) NO20033816L (fr)
NZ (2) NZ622900A (fr)
OA (1) OA12590A (fr)
PL (1) PL226184B1 (fr)
PT (2) PT1355673E (fr)
RO (1) RO122761B1 (fr)
SI (1) SI21352A (fr)
TN (1) TNSN03041A1 (fr)
UA (1) UA92579C2 (fr)
WO (1) WO2002058737A2 (fr)
YU (1) YU66103A (fr)
ZA (1) ZA200306176B (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
AP1897A (en) 2001-01-23 2008-10-10 Aventis Pasteur Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine.
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2014218428B2 (en) * 2001-06-20 2016-08-25 Glaxosmithkline Biologicals Sa Capsular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
AU2003299501A1 (en) * 2002-05-16 2004-05-04 Aventis Pasteur, Inc. Animal component free meningococcal polysaccharide fermentation and seedbank development
WO2004011027A1 (fr) * 2002-07-30 2004-02-05 Baxter International Inc. Vaccins multivalents chimeres a conjugue polysaccharidique
BR0316271A (pt) * 2002-11-14 2005-10-11 Inst Finlay Ct De Investigacio Método para a obtenção de preparados vacinais conjugados multivalentes, composição vacinal multivalente e uso da mesma
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US10272147B2 (en) 2003-01-30 2019-04-30 Glaxosmithkline Biologicals S.A. Injectable vaccines against multiple meningococcal serogroups
WO2004080490A2 (fr) * 2003-03-07 2004-09-23 Wyeth Holdings Corporation Conjugues de proteine-polysaccharide porteuse d'adhesine superficielle staphylococcique pour immunisation contre des infections nosocomiales
BRPI0410423A (pt) * 2003-05-07 2006-06-06 Sanofi Pasteur Inc processo de imunogenicidade melhorada para vacinação meningocócica
ES2596553T3 (es) * 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
EP2364725A3 (fr) * 2003-06-23 2012-05-09 Sanofi Pasteur Inc. Procédé d'immunisation contre les sérogroupes A et C de Neisseria Meningitidis
US20070020293A1 (en) * 2003-06-23 2007-01-25 Michon Francis J Vaccines against group neisseria meningitidis and meningococcal combinations thereof
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
US8765135B2 (en) * 2003-10-02 2014-07-01 Novartis Ag Liquid vaccines for multiple meningococcal serogroups
GB0406013D0 (en) * 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
AU2011204789B2 (en) * 2004-04-22 2013-07-11 Glaxosmithkline Biologicals S.A. Immunising against meningococcal serogroup Y using proteins
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
EP1740217B1 (fr) * 2004-04-30 2011-06-15 Novartis Vaccines and Diagnostics S.r.l. Integration d'une vaccination conjuguee antimeningococcique
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
BRPI0515125A (pt) * 2004-08-30 2008-07-08 Sanofi Pasteur Inc conjugados de polissacarìdeo derivatizado-proteìna multivalentes, meningocócicos e vacina
GB0419846D0 (en) * 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
BRPI0516770A (pt) * 2004-09-21 2008-09-23 Sanofi Pasteur Inc vacina e conjugados de proteìna - derivados de polissacarìdeo de meningocócico multivalente
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
EP1871411A4 (fr) 2005-04-18 2010-07-21 Novartis Vaccines & Diagnostic Procede pour exprimer un antigene de surface de virus de l'hepatite b afin de preparer un vaccin
US8431136B2 (en) 2005-06-27 2013-04-30 Glaxosmithkline Biologicals S.A. Immunogenic composition
NZ598367A (en) 2005-09-01 2013-10-25 Novartis Vaccines & Diagnostic Multiple vaccination including serogroup C meningococcus
US20070065462A1 (en) * 2005-09-21 2007-03-22 Ryall Robert P Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
EP1993604B1 (fr) 2006-03-17 2015-12-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Procédé de préparation de conjugués immunogéniques multivalents complexes
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
NZ572054A (en) * 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
US8414899B2 (en) 2006-04-11 2013-04-09 Yeda Research And Development Co. Ltd. Vaccines comprising multimeric HSP60 peptide carriers
MX2009013112A (es) 2007-06-04 2010-03-01 Novartis Ag Formulacion de vacunas para meningitis.
MX340096B (es) 2007-10-19 2016-06-27 Glaxosmithkline Biologicals Sa Formulaciones de vacuna meningococica.
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EP2367568A2 (fr) 2008-12-17 2011-09-28 Novartis AG Vaccins méningococciques comprenant un récepteur de l'hémoglobine
US8003112B2 (en) * 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
JP5781542B2 (ja) * 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
EP2547357A1 (fr) 2010-03-18 2013-01-23 Novartis AG Vaccins adjuvantés contre le méningocoque de sérogroupe b
CA2808975C (fr) 2010-08-23 2018-10-30 Wyeth Llc Formulations stables des antigenes rlp2086 de neisseria meningitidis
ES2744471T3 (es) * 2010-09-04 2020-02-25 Glaxosmithkline Biologicals Sa Ensayos de anticuerpos bactericidas para evaluar la inmunogenia y la potencia de vacunas de sacárido capsular meningocócico
ES2864635T3 (es) 2010-09-10 2021-10-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
ES2681698T3 (es) 2011-03-02 2018-09-14 Glaxosmithkline Biologicals Sa Vacunas de combinación con menores dosis de antígeno y/o adyuvante
JP6088507B2 (ja) 2011-07-08 2017-03-01 ノバルティス アーゲー チロシンライゲーションの方法
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
JP2015509963A (ja) 2012-03-08 2015-04-02 ノバルティス アーゲー Ｔｌｒ４アゴニストを含む混合ワクチン
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2822583A2 (fr) 2012-03-09 2015-01-14 Pfizer Inc. Compositions de neisseria meningitidis et procédés associés
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
AU2013265336A1 (en) 2012-05-22 2014-12-04 Novartis Ag Meningococcus serogroup X conjugate
ES2800479T3 (es) * 2012-08-16 2020-12-30 Pfizer Procedimientos y composiciones de glucoconjugación
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
CA2894260A1 (fr) 2012-12-18 2014-06-26 Glaxosmithkline Biologicals S.A. Conjugues de protection contre la diphterie et/ou le tetanos
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
BE1021934B1 (fr) * 2013-03-18 2016-01-27 Glaxosmithkline Biologicals S.A. Procede de traitement
JP6739333B2 (ja) 2013-07-11 2020-08-12 ノバルティス アーゲー 部位特異的化学酵素的タンパク質修飾
CN105492021B (zh) 2013-09-08 2018-12-04 辉瑞公司 脑膜炎奈瑟氏球菌组合物及其方法
WO2015181834A2 (fr) 2014-05-24 2015-12-03 Biological E Limited Nouveau vaccin conjugué méningococcique semi-synthétique
MX2017010705A (es) 2015-02-19 2017-12-04 Pfizer Composiciones de neisseria meningitidis y metodos de la misma.
JP6830896B2 (ja) 2015-02-20 2021-02-17 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 溶解ガス発生流体を有するコントラスト造影剤
KR20160011136A (ko) 2015-03-25 2016-01-29 한국기계연구원 내식성이 향상된 마그네슘 합금 및 이를 이용하여 제조한 마그네슘 합금 부재의 제조방법
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
RS63450B1 (sr) 2015-12-30 2022-08-31 Ascendis Pharma As Auto-injektor sa sistemom za zadržavanje kertridža
KR102204927B1 (ko) 2016-07-25 2021-01-19 에스케이바이오사이언스(주) 피막 다당류-단백질 접합 백신의 품질 평가 방법
CA3033364A1 (fr) * 2016-09-02 2018-03-08 Sanofi Pasteur, Inc. Vaccin contre neisseria meningitidis
AU2017321039B2 (en) 2016-09-02 2021-03-18 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
IL303108B1 (en) 2017-01-31 2024-03-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
WO2019198096A1 (fr) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Composition de vaccin méningococcique tétravalente et son procédé de préparation
EP3632465A1 (fr) 2018-10-03 2020-04-08 Sanofi Pasteur Inc. Immunisation combinée contre la méningite à méningocoques et le papillomavirus humain
WO2020168146A1 (fr) * 2019-02-14 2020-08-20 University Of Florida Research Foundation, Inc. Vaccin à base de snodgrassella alvi commensale d'abeilles contre neisseriaceae pathogènes
CN110903388B (zh) * 2019-12-03 2024-01-02 兰州生物制品研究所有限责任公司 一种将脑膜炎球菌抗血清去交叉反应的方法
US11737987B2 (en) 2019-12-17 2023-08-29 9286-3620 Quebec Inc. Oral delivery systems based on in situ forming protein/polysaccharide coacervates
KR102610292B1 (ko) 2021-02-10 2023-12-04 에스케이바이오사이언스(주) 스트랩토코커스 뉴모니애 다당류와 운반체 단백질의 접합체 제조 방법
US20220265805A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
WO2023200704A1 (fr) 2022-04-11 2023-10-19 Sanofi Pasteur Inc. Conjugaison protéine-saccharide avec du cyanoborohydrure de sodium
WO2024030931A1 (fr) 2022-08-03 2024-02-08 Sanofi Pasteur Inc. Composition immunogène à adjuvant contre neisseria meningitidis b

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351761A (en) 1978-05-15 1982-09-28 Research Corporation Purified antigen to test for Neisseria gonorrhoeae antibodies
US4404371A (en) 1981-01-14 1983-09-13 Battelle Memorial Institute Carboxymethylcellulose with carbonate bridges and preparation thereof
US4351762A (en) * 1981-03-10 1982-09-28 Bioresearch, Inc. Rapid, quantitative peptide synthesis using mixed anhydrides
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
DE3382737T2 (de) 1982-11-10 1994-05-19 Mitsubishi Heavy Ind Ltd Nickel-Chrom-Legierung.
US4762713A (en) 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
ATE38064T1 (de) 1985-04-17 1988-11-15 Akzo Nv Verfahren zum anbringen einer wegmarkierungszusammensetzung.
DE3518706A1 (de) 1985-05-24 1986-11-27 Kernforschungszentrum Karlsruhe Gmbh, 7500 Karlsruhe Verfahren zur herstellung von formkoerpern mit verbesserten, isotropen eigenschaften
US4814276A (en) 1986-04-25 1989-03-21 Becton, Dickinson And Company Selective medium for growth of neisseria
WO1990006696A2 (fr) 1988-12-19 1990-06-28 Praxis Biologics, Inc. Vaccin meningocoque de la proteine de la membrane externe de la classe 1
US4963534A (en) 1989-05-19 1990-10-16 Merck & Co., Inc. Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents
NZ239643A (en) 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
WO1992016232A1 (fr) 1991-03-12 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Conjugues de polysaccharide-proteine
SK18594A3 (en) 1991-08-16 1994-08-10 Merck & Co Inc Method of production of capsular polysacharide without lipid and endotoxine
US5314811A (en) 1992-07-13 1994-05-24 Merck & Co., Inc. Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
US5422427A (en) 1991-09-17 1995-06-06 The United States Of America As Represented By The United States Department Of Health And Human Services Pneumococcal fimbrial protein A
FR2682388B1 (fr) 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
DK0835663T3 (da) * 1992-05-23 2010-02-01 Glaxosmithkline Biolog Sa Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener
US5445817A (en) 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
PT658118E (pt) * 1992-08-31 2002-05-31 Baxter Healthcare Sa Vacinas contra neisseria meningitidis do grupo c
CA2222455C (fr) 1995-03-22 2013-05-28 Smithkline Beecham Biologicals S.A. Composition de vaccin comportant un antigene polyosidique conjugue adsorbe sur du phosphate d'aluminium
US20030157129A1 (en) 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
DK1090642T3 (da) 1995-06-07 2008-09-22 Glaxosmithkline Biolog Sa Vacciner omfattende et polysaccharidantigen-bæreprotein-konjugat og frit bæreprotein
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US6248334B1 (en) 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
ES2335557T3 (es) 1997-01-21 2010-03-29 Sanofi Pasteur Conjugados de peptido-polisacarido.
EP0975790B1 (fr) 1997-01-24 2004-09-29 Schweiz. Serum-&Impfinstitut Bern Nouveau procede pour isoler des polysaccharides
US6403306B1 (en) 1997-04-09 2002-06-11 Emory University Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto
ATE278418T1 (de) 1997-04-24 2004-10-15 Jackson H M Found Military Med Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen
WO1998054296A1 (fr) 1997-05-28 1998-12-03 Chiron S.P.A. Milieu de culture renfermant de la levure ou de l'extrait de soja comme sources d'acides amines mais exempt de complexes proteiniques d'origine animale
US6413520B1 (en) 1997-06-24 2002-07-02 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
ES2346022T3 (es) 1997-12-23 2010-10-07 Baxter Healthcare S.A. Procedimiento para la extraccion y el aislamiento de polisacaridos capsulares bacterianos para su uso como vacunas o ligandos a proteinas como vacunas de conjugados.
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
PT1147117E (pt) 1999-02-01 2004-10-29 Eisai Co Ltd Compostos adjuvantes imunologicos
KR20020000785A (ko) * 1999-03-19 2002-01-05 장 스테판느 백신
EP1860191A3 (fr) 1999-05-19 2008-02-13 Novartis Vaccines and Diagnostics S.r.l. Compositions à base de combinaisons de Neisseria
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
ATE400296T1 (de) 1999-12-02 2008-07-15 Novartis Vaccines & Diagnostic Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
US6800455B2 (en) * 2000-03-31 2004-10-05 Scios Inc. Secreted factors
CZ20024224A3 (cs) 2000-06-29 2003-05-14 Glaxosmithkline Biologicals S. A. Farmaceutický prostředek
AP1897A (en) * 2001-01-23 2008-10-10 Aventis Pasteur Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine.
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination

Also Published As

Publication number Publication date
BRPI0206672B1 (pt) 2018-11-06
US20190060475A1 (en) 2019-02-28
AP1897A (en) 2008-10-10
NO20033816D0 (no) 2003-08-27
OA12590A (en) 2006-06-08
EA200300827A1 (ru) 2004-06-24
AP2003002829A0 (en) 2003-09-30
US8999354B2 (en) 2015-04-07
CY2012030I2 (el) 2016-08-31
HUS1600040I1 (hu) 2019-05-28
HUP0302999A2 (hu) 2003-12-29
US20160000928A1 (en) 2016-01-07
HUP0302999A3 (en) 2011-05-30
MXPA03006561A (es) 2004-10-15
FR15C0094I1 (fr) 2016-01-22
SI21352A (sl) 2004-06-30
WO2002058737A2 (fr) 2002-08-01
ECSP034701A (es) 2003-10-28
TNSN03041A1 (en) 2005-12-23
YU66103A (sh) 2006-05-25
US8741314B2 (en) 2014-06-03
US8722062B2 (en) 2014-05-13
CA2435681C (fr) 2011-06-21
IL225522A (en) 2016-04-21
US20150174259A1 (en) 2015-06-25
JP2014065745A (ja) 2014-04-17
BE2022C502I2 (fr) 2023-04-12
UA92579C2 (ru) 2010-11-25
LT2003071A (en) 2004-08-25
FR12C0072I2 (fr) 2013-11-01
US20030068336A1 (en) 2003-04-10
BR0206672A (pt) 2005-05-10
CY1113072T1 (el) 2015-08-05
JP2014043474A (ja) 2014-03-13
HRP20030598B1 (hr) 2013-05-31
JP2014043475A (ja) 2014-03-13
RO122761B1 (ro) 2010-01-29
US10617766B2 (en) 2020-04-14
WO2002058737A3 (fr) 2003-05-22
JP5795721B2 (ja) 2015-10-14
LU92108I2 (fr) 2013-01-29
EP2957300B1 (fr) 2021-07-14
IS6881A (is) 2003-07-22
GEP20053691B (en) 2005-12-12
BE2015C077I2 (fr) 2021-02-04
CA2435681A1 (fr) 2002-08-01
US9844601B2 (en) 2017-12-19
ZA200306176B (en) 2005-03-30
HRP20030598A2 (en) 2005-06-30
PL226184B1 (pl) 2017-06-30
LU92108I9 (fr) 2019-01-15
EP2332581B1 (fr) 2015-07-01
FR12C0072I1 (fr) 2013-01-04
CR7035A (es) 2008-11-25
HU230490B1 (hu) 2016-08-29
JP2016128526A (ja) 2016-07-14
KR100947751B1 (ko) 2010-03-18
EP2957300A2 (fr) 2015-12-23
EP1355673B1 (fr) 2012-05-30
AU2007216743A1 (en) 2007-10-04
EA006947B1 (ru) 2006-06-30
KR20030084913A (ko) 2003-11-01
CN1610560A (zh) 2005-04-27
ES2388848T3 (es) 2012-10-19
US10143757B2 (en) 2018-12-04
PT2332581E (pt) 2015-10-16
ES2892316T3 (es) 2022-02-03
DK1355673T3 (da) 2012-09-17
JP2011140522A (ja) 2011-07-21
FR15C0094I2 (fr) 2017-05-19
CY2012030I1 (el) 2015-08-05
US20130224241A1 (en) 2013-08-29
FR22C1001I1 (fr) 2022-02-18
EP1355673A2 (fr) 2003-10-29
IL157060A0 (en) 2004-02-08
IL157060A (en) 2013-04-30
JP2005504718A (ja) 2005-02-17
AU2010219288A1 (en) 2010-09-23
US20130216571A1 (en) 2013-08-22
LV13128B (en) 2004-07-20
PL373710A1 (en) 2005-09-05
NZ602682A (en) 2014-05-30
US9173955B2 (en) 2015-11-03
US20140308311A1 (en) 2014-10-16
US8734813B2 (en) 2014-05-27
US20130177588A1 (en) 2013-07-11
US20180154010A1 (en) 2018-06-07
ES2544979T3 (es) 2015-09-07
EP2957300A3 (fr) 2016-03-30
NZ622900A (en) 2015-11-27
NO20033816L (no) 2003-09-11
DK2332581T3 (en) 2015-10-05
EP2332581A1 (fr) 2011-06-15
IL225522A0 (en) 2013-06-27
PT1355673E (pt) 2012-08-31
KR20090029857A (ko) 2009-03-23
MX341760B (es) 2016-09-02
BRPI0206672B8 (pt) 2021-05-25
CN100556459C (zh) 2009-11-04
KR100947757B1 (ko) 2010-03-18
LT5177B (lt) 2004-11-25

Similar Documents

Publication Publication Date Title
BE2022C531I2 (fr)
BE2022C502I2 (fr)
BE2022C547I2 (fr)
BE2017C056I2 (fr)
BE2017C051I2 (fr)
BE2017C032I2 (fr)
BE2016C051I2 (fr)
BE2015C046I2 (fr)
BE2014C052I2 (fr)
BE2014C036I2 (fr)
BE2014C026I2 (fr)
BE2014C004I2 (fr)
BE2014C006I2 (fr)
BE2017C050I2 (fr)
BE2011C034I2 (fr)
BE2007C047I2 (fr)
AU2002307149A8 (fr)
BRPI0209186B1 (fr)
BE2014C008I2 (fr)
BRPI0204884B1 (fr)
BE2016C021I2 (fr)
BE2017C059I2 (fr)
JP2002230544A5 (fr)
BRPI0101486B8 (fr)
BE2012C051I2 (fr)